Chongqing Beer Two-month share price doubled the system has made a big profit of 350%

From 35 yuan to 73 yuan, a short period of two months, Chongqing beer (600132. SH) has doubled. The dominant surge is a hepatitis B vaccine that is being studied by Chongqing beer and looks promising. The big fund, which had been lurking in the early 2009, has now received 350% of its book earnings.　　Even so, there is still disagreement among the market parties. The study on hepatitis B vaccine by Chongqing Beer began in 1998. However, the development of new drugs has never been smooth sailing. 2003, the treatment of hepatitis B vaccine into Phase I clinical, the results proved that the safety of the requirements; 2006 into Phase II stage a clinical, but in the 48-week observation period, the subjects not only did not appear virus DNA decline, even the immune level is low,　　It seems that vaccines have no effect on chronic hepatitis B patients. The result is far below market expectations and is a serious blow to the share price of Chongqing beer.　　In June 2007, the company's share price began to fall after a record high, from June 13, 2007 's 41 Yuan High, has been adjusted to October 2008, the lowest to 8 yuan below the decline of 80%. The fund also abandoned Chongqing beer at this time.　　Public data show that, in 2007 years, there are 15 funds holding Chongqing beer, the proportion of shares in the shares of 9.2%, and by the end of 2007, the proportion of the Fund's share of shares in circulation has plummeted to less than 5%. However, in the market cold watch Hepatitis B vaccine, the big fund in the first quarter of 2009 years to enter the unit. Data show that at the end of 2008, there was only one big into the Shanghai and Shenzhen 300 Index fund to hold 0.14% circulating shares of Chongqing Beer, and by 2009 quarter, the big into innovative growth, big into wealth management 2020, large into the value of growth, large into the optimization, the fund Gyeongbokgung, the big into the leading,　　Big into positive growth and so on 7 funds Qi Qi appeared in its top ten circulating shares of shareholders, the total shareholding ratio reached 12%, accounting for the proportion of total equity also more than 8%. At this time, the market also optimistic about Chongqing beer and ping an securities. February 26, 2009, Ping An securities and pharmaceutical industry researcher Lio Van released a report that Chongqing beer developed by the treatment (synthetic peptide) Hepatitis B vaccine is the history of hepatitis B treatment in the field of treatment drugs, the product is very likely to be marketed after 3 years, become the first choice for the treatment of hepatitis B drugs. "Conservatively measured in the first year after the listing can achieve nearly 500 million yuan sales revenue and 200 million yuan net profit, after the listing within 10 years will likely have 30% growth rate, generate tens of billions of yuan sales revenue." "But the market does not match.　　2009, the Shanghai Composite Index rose 80%, Chongqing beer shares only a small rise of 27%, after entering 2010, and continue to 22 to 23 yuan position consolidation for several months. The turning point came in September this year. September 2, Chongqing Beer released "on the Treatment (synthetic peptide) hepatitis B vaccine Research Progress Bulletin", which entered Phase II clinical trial after the fourth study Progress Bulletin. XingIndustry securities researcher Wang Yu released report comments, prompted the market attention, "the North group Progress smoothly, Zhejiang University Group of patients to speed up, this is a very good phenomenon." The curative effect of therapeutic hepatitis B vaccine is accurate and safe and effective. It is more likely than the existing drugs, the future is very promising to become the treatment of chronic hepatitis B first-line drugs. The market value of therapeutic Hepatitis B vaccine will be fully understood in the future with the development of clinical trials. In the report, Wang Xi maintained a "strong recommendation" rating for the company.　　In fact, since August 2009, Wang Yu has published 21 consecutive research reports on Chongqing Beer, with a rating of "highly recommended". After September, Chongqing Beer finally began to explode, in less than three months, the share price has soared to 72 yuan, the rise is nearly 100%. After waiting 1.5 time, the big fund finally waits for the Chongqing beer reverse.　　According to its average holding cost of about 16 yuan, the big fund has already gained 350% of its book income in the investment. Other funds have also been involved in the unit since the beginning of this year.　　At the end of 2009, the Fund's ownership of Chongqing beer accounted for about 15% of the shares, and in 2010, the fund held more than 25%. But there are still institutions that are skeptical about the hepatitis B vaccine. Hongyuan Securities analyst Su Jinghan in the 2009 Annual report of Chongqing Beer that the vaccine may become the company's performance points and price catalysts, but it is expected to complete the three-phase clinical trial and officially listed at least two time, the recent contribution to the company's performance is small, and the company's overall development strategy may form interference. A fund manager in Shenzhen is also worried that stock prices, pulled up by the notion of a non-business concept, may not last.